Plasma Cell-Rich Acute Rejection in Renal Transplantation: A Case Report

• Published in: Transplantation proceedings 2020-03, Vol.52 (2), p.512-514
• Main Authors: Plaza Lara, Eva, Hernández García, Elena, Ruiz Fuentes, Maria del Carmen, Caba Molina, Mercedes, De Gracia Guindo, Maria del Carmen, Osuna Ortega, Antonio
• Format: Article
• Language: English
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2019.12.015

Plasma cell-rich acute rejection (PCAR) is a rare type of allograft rejection in renal transplantation. It is characterized by the presence of mature plasma cells that compromise more than 10% of inflammatory cells infiltrating the renal graft. The pathogenesis of PCAR is unknown, appears late, and has been related mainly to insufficient immunosuppression or infections. The treatment is not clearly defined, and the graft survival is poor. Here, we report a case series of 3 Spanish patients diagnosed with PCAR accompanied by donor-specific antibodies (DSA) after kidney transplantation. Mean to diagnosis was 2-12 years post-transplantation, and they began with abrupt deterioration of renal function. All patients were women and had preceding viral infection. In addition, two of the three patients recognize a doubtful adherence to immunosuppression. About treatment, 2 of the 3 patients, because the biopsy of the renal graft showed signs suggestive of incipient antibody-mediated rejection (ABMR) (glomerulitis, capilaritis, transplant glomerulopathy), were started with corticosteroids, anti-thymoglobulin, plasmapheresis, and intravenous immunoglobulins. The last patient, who only showed PCAR at biopsy, was treated with corticosteroids and anti-thymoglobulin. After treatment, graft function improved in all of them, but one patient developed an ABMR and another required a dialysis program, all of which indicates the difficulty in management and treatment of PCAR. •Plasma cell-rich acute rejection is a rare type of allograft rejection in renal transplantation.•This type of allograft rejection has been related mainly to insufficient immunosuppression or infections.•This pathology presents de novo donor-specific antibodies.•It is a entity refractory to treatment and with a graft survival of around 50%.